Peptide Therapeutics Market: By Type (Branded Peptide, Generic Peptide), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, Others), By Route of Administration (Oral Administration, Parenteral Administration, Pulmonary Administration, Mucosal Administration, Injection Administration), and Region:Cumulative Growth Opportunities Analysis, Size, Share, Trends, and Industry Forecast Till 2030.

Report ID : AMR1004146 | Industries : Healthcare | Published On :December 2023 | Page Count : 210

Peptide Therapeutics Market: By Type (Branded Peptide, Generic Peptide), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, Others), By Route of Administration (Oral Administration, Parenteral Administration, Pulmonary Administration, Mucosal Administration, Injection Administration), and Region – Cumulative Growth Opportunities Analysis, Size, Share, Trends, and Industry Forecast Till 2030.

Market Overview:

• The Global Peptide Therapeutics was valued at USD 44,699.15 million in 2022.
• It is expected to reach USD 68,553.89 million by 2030, with a CAGR of 12.5% during 2023-2030.
• The report analyzes the market by type, application, route of administration and region, offering insights on market dynamics and competitive assessment of major players.

The research report analyzes the profound and enduring impact of the Russia-Ukraine Conflict, High Inflation, and the Cumulative Impact of COVID-19 on the Global Peptide Therapeutics. It delves into the ways the pandemic has transformed consumer behavior, disrupted supply chains, and triggered governmental responses. The report also examines the economic and political turbulence in Eastern Europe caused by the Russia-Ukraine Conflict, with a focus on its potential ramifications for demand-supply balances, pricing fluctuations, and international trade. Furthermore, the research addresses the implications of high inflation on the global economy and provides an in-depth overview of fiscal measures adopted to monitor and mitigate its effects on demand, supply, cash flow, and currency exchange in the market. The report aims to equip stakeholders with valuable insights to navigate the challenges arising from these geopolitical and economic disruptions, ensuring informed decision-making and strategic planning.

Competitive Landscape:

The competitive landscape analysis within the Peptide Therapeutics entails a thorough evaluation of prominent market players, encompassing an examination of their market share, product portfolios, recent advancements, strategies, partnerships, and merger/acquisition activities. This comprehensive assessment offers invaluable insights into the competitive dynamics, enabling stakeholders to comprehend the positioning of each player within the market. To gauge their internal capabilities, vulnerabilities, and external market influences affecting their competitiveness, a SWOT analysis (Strengths, Weaknesses, Opportunities, and Threats) is performed for each major player. Such a meticulous analysis facilitates the identification of competitive advantages and areas for improvement for each player.
Overall, the competitive landscape analysis presents a holistic view of the Peptide Therapeutics, highlighting key players, their market shares, product offerings, recent developments, strategies, and SWOT analysis. This wealth of information empowers stakeholders to make informed decisions, devise effective strategies, and pinpoint potential partnerships or investment opportunities, fostering a deeper understanding of the market's competitive dynamics.

Key Players:

The research report thoroughly analyses the most significant recent advancements by the top players and innovation profiles in the global Peptide Therapeutics, comprising: F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd, (Israel), Ipsen Pharma (France), AstraZeneca (UK), Lonza (Switzerland), Merck Sharp & Dohme Corp. (U.S.).

Porter's Five Forces Analysis:

Porter's Five Forces analysis is a strategic framework used to assess the competitive forces within an industry. It considers five key factors: the threat of new entrants, bargaining power of buyers, bargaining power of suppliers, threat of substitutes, and intensity of competitive rivalry. The analysis helps businesses understand the overall industry attractiveness and profitability by identifying the forces that shape competition and influence market dynamics. High barriers to entry, strong buyer or supplier power, limited substitute options, and intense rivalry can reduce industry attractiveness and impact profitability. Conversely, industries with low barriers, weak supplier and buyer power, and limited substitutes tend to be more attractive and profitable.

Regional Outlook:

The comprehensive analysis of the Global Peptide Therapeutics encompasses significant geographic regions, namely North America, Europe, Asia Pacific, and the rest of the world. Within each of these areas, the report may include detailed analysis at the country level, providing valuable insights into market dynamics, prevailing trends, and distinctive opportunities specific to each geographical location. This regional breakdown sheds light on the varying market conditions for Peptide Therapeutics, empowering stakeholders to adapt their strategies and investments according to the distinct dynamics and prospects in each region. By leveraging the regional analysis, stakeholders can gain a deeper understanding of the market's regional variations and make informed decisions to capitalize on the unique opportunities present in different parts of the world.

Scope of Global Peptide Therapeutics:

1. By Type:
• Branded Peptide
• Generic Peptide
2. By Application
• Cancer
• Velcade (Bortezomib)
• Zoladex (Goserelin)
• Lupron/ Enantone/ Eligard (Leuprorelin)
• Cardiovascular Disease
• Integrilin (Eptifibatide)
• Angiomax (Bivalirudin)
• Metabolic Disease
• Byetta (Exenatide)
• Victoza (Liraglutide)
• Respiratory Disease
• Gastro-Intestinal Infection (GIT)
• 1 Linzess (Linaclotide)
• Gattex (Teduglutide)
• Infectious Disease
• Victrelis (Boceprevir)
• Incivek (Telaprevir)
• Hematological Disorders
• Kalbitor (Ecallantide)
• Firazyr (Icatibant)
• Others
3. By Route of Administration
• Oral Administration
• Parenteral Administration
• Pulmonary Administration
• Mucosal Administration
• Injection Administration
• Offline mode
4. By Region:
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa

The report provides valuable insights based on the following key guidelines, offering a comprehensive understanding of the market dynamics:

1. Market Trends: The report goes beyond surface-level analysis and delves deep into the market trends, particularly focusing on the cumulative impact of COVID-19, the implications of the nearing economic downturn, the conflict in Russia and Ukraine, and the effects of the high inflation rate on the industry.
2. Market Segmentation Analysis: An in-depth segmentation analysis of the market is conducted, categorizing it based type, application, route of administration and geographical regions. This approach offers a granular understanding of different market segments and their individual growth potential.
3. Competitive Assessment & Intelligence: A thorough and detailed analysis of major companies operating in the market is provided. The assessment includes their market shares, business plans, product portfolios, certifications, legal permits, patent landscape, and manufacturing capabilities, enabling stakeholders to make informed decisions.
4. Mergers and Acquisitions: This section provides insights into recent mergers, acquisitions, and partnerships within the industry. The report evaluates the strategic rationale behind these collaborations and their potential implications on market competition.
5. Post-Pandemic Recovery Strategies: An exploration of post-pandemic recovery strategies is offered, highlighting successful approaches employed by companies to bounce back from the challenges posed by COVID-19.
6. Market Penetration: Detailed information about the market is presented, with a specific focus on major players. Their strategies, market presence, and overall impact on the industry are thoroughly examined to provide a clear picture of market penetration.
7. Product Development & Innovation: The report offers insightful perspectives on emerging technologies, research and development initiatives, and groundbreaking product developments within the market. This section aims to keep stakeholders updated on the latest innovations driving the industry forward.
8. Emerging Market Opportunities: Identifying emerging market opportunities and niche segments within the industry is crucial for companies seeking to expand their market presence. The report highlights potential growth areas that might be overlooked but hold promising prospects.

The report provides stakeholders with extensive insights to facilitate well-informed decision-making and effective strategic planning for the future. Additionally, it addresses the following questions:

• How does the regional market size and growth forecast vary for different geographic segments within the Global Peptide Therapeutics?
• What are the key growth drivers and potential challenges for the Global Peptide Therapeutics, and how do they impact market dynamics during the forecast period?
• Which specific product types or application areas within the Global Peptide Therapeutics show the highest growth potential and investment opportunities in the coming years?
• What recent technology trends are influencing the development and adoption of Peptide Therapeutics globally, and what regulatory frameworks are governing their use in different regions?
• How does the market share of the leading vendors in the Global Peptide Therapeutics compare, and what factors contribute to their competitive positions?
• What entry strategies and modalities should new players consider to enter the Global Peptide Therapeutics effectively, and what are the potential risks and rewards associated with each approach?
• How do pricing trends for Peptide Therapeutics vary across different regions and product categories, and what strategies can vendors implement to maintain competitive pricing?
• How has the COVID-19 pandemic affected the Global Peptide Therapeutics, and what are the limiting factors impacting its growth during the projected time frame?

Frequently Asked Questions (FAQ) regarding the Global Peptide Therapeutics:

What is the anticipated size of the global market for Peptide Therapeutics?
What is the market size for the Peptide Therapeutics globally?
What is the projected size of the global market for Peptide Therapeutics?
Who are the most prominent companies in the global market for Peptide Therapeutics?

Global Peptide Therapeutics Market

1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Peptide Therapeutics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to Recent Energy Crisis
4.2.5 Cumulative Impact due to Nearing Economic Downturn
4.2.6 Post Covid-19 World Supply & Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Peptide Therapeutics Market, By Type
5.1 Y-o-Y Growth Comparison, By Type
5.2 Global Peptide Therapeutics Market Share Analysis, By Type
5.3 Global Peptide Therapeutics Market Size and Forecast, By Type
5.3.1 Branded Peptide
5.3.2 Generic Peptide
6 Global Peptide Therapeutics Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Peptide Therapeutics Market Share Analysis, By Application
6.3 Global Peptide Therapeutics Market Size and Forecast, By Application
6.3.1 Cancer
6.3.2 Velcade (Bortezomib)
6.3.3 Zoladex (Goserelin)
6.3.4 Lupron/ Enantone/ Eligard (Leuprorelin)
6.3.5 cardiovascular disease
6.3.6 Integrilin (Eptifibatide)
6.3.7 Angiomax (Bivalirudin)
6.3.8 Metabolic Disease
6.3.9 Byetta (Exenatide)
6.3.10 Victoza (Liraglutide)
6.3.11 respiratory disease
6.3.12 Gastro-Intestinal Infection (GIT)
6.3.13 1 Linzess (Linaclotide)
6.3.14 Gattex (Teduglutide)
6.3.15 Infectious Disease
6.3.16 Victrelis (Boceprevir)
6.3.17 Incivek (Telaprevir)
6.3.18 Hematological Disorders
6.3.19 Kalbitor (Ecallantide)
6.3.20 Firazyr (Icatibant)
6.3.21 Others
7 Global Peptide Therapeutics Market, By Route of Administration
7.1 Y-o-Y Growth Comparison, By Route of Administration
7.2 Global Peptide Therapeutics Market Share Analysis, By Route of Administration
7.3 Global Peptide Therapeutics Market Size and Forecast, By Route of Administration
7.3.1 Oral Administration
7.3.2 Parenteral Administration
7.3.3 Pulmonary Administration
7.3.4 Mucosal Administration
7.3.5 Injection Administration
8 Global Peptide Therapeutics Market, By Region
8.1 Global Peptide Therapeutics Market Share Analysis, By Region
8.2 Global Peptide Therapeutics Market Size and Forecast, By Region
8.3 Global Peptide Therapeutics Market Trends and Forecast, By Region
9 North America Peptide Therapeutics Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America Peptide Therapeutics Market Size and Forecast, By Type
9.3 North America Peptide Therapeutics Market Size and Forecast, By Application
9.4 North America Peptide Therapeutics Market Size and Forecast, By Route of Administration
9.5 North America Peptide Therapeutics Market Size and Forecast, By Country
9.5.1 U.S.
9.5.1.1 Market Size and Forecast, By Type
9.5.1.2 Market Size and Forecast, By Application
9.5.1.3 Market Size and Forecast, By Route of Administration
9.5.2 Canada
9.5.2.1 Market Size and Forecast, By Type
9.5.2.2 Market Size and Forecast, By Application
9.5.2.3 Market Size and Forecast, By Route of Administration
9.5.3 Mexico
9.5.3.1 Market Size and Forecast, By Type
9.5.3.2 Market Size and Forecast, By Application
9.5.3.3 Market Size and Forecast, By Route of Administration
10 Europe Peptide Therapeutics Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe Peptide Therapeutics Market Size and Forecast, By Type
10.3 Europe Peptide Therapeutics Market Size and Forecast, By Application
10.4 Europe Peptide Therapeutics Market Size and Forecast, By Route of Administration
10.5 Europe Peptide Therapeutics Market Size and Forecast, By Country
10.5.1 Germany
10.5.1.1 Market Size and Forecast, By Type
10.5.1.2 Market Size and Forecast, By Application
10.5.1.3 Market Size and Forecast, By Route of Administration
10.5.2 France
10.5.2.1 Market Size and Forecast, By Type
10.5.2.2 Market Size and Forecast, By Application
10.5.2.3 Market Size and Forecast, By Route of Administration
10.5.3 UK
10.5.3.1 Market Size and Forecast, By Type
10.5.3.2 Market Size and Forecast, By Application
10.5.3.3 Market Size and Forecast, By Route of Administration
10.5.4 Russia
10.5.4.1 Market Size and Forecast, By Type
10.5.4.2 Market Size and Forecast, By Application
10.5.4.3 Market Size and Forecast, By Route of Administration
10.5.5 Italy
10.5.5.1 Market Size and Forecast, By Type
10.5.5.2 Market Size and Forecast, By Application
10.5.5.3 Market Size and Forecast, By Route of Administration
10.5.6 Spain
10.5.6.1 Market Size and Forecast, By Type
10.5.6.2 Market Size and Forecast, By Application
10.5.6.3 Market Size and Forecast, By Route of Administration
10.5.7 Rest of Europe
10.5.7.1 Market Size and Forecast, By Type
10.5.7.2 Market Size and Forecast, By Application
10.5.7.3 Market Size and Forecast, By Route of Administration
11 Asia Pacific Peptide Therapeutics Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific Peptide Therapeutics Market Size and Forecast, By Type
11.3 Asia Pacific Peptide Therapeutics Market Size and Forecast, By Application
11.4 Asia Pacific Peptide Therapeutics Market Size and Forecast, By Route of Administration
11.5 Asia Pacific Peptide Therapeutics Market Size and Forecast, By Country
11.5.1 China
11.5.1.1 Market Size and Forecast, By Type
11.5.1.2 Market Size and Forecast, By Application
11.5.1.3 Market Size and Forecast, By Route of Administration
11.5.2 Japan
11.5.2.1 Market Size and Forecast, By Type
11.5.2.2 Market Size and Forecast, By Application
11.5.2.3 Market Size and Forecast, By Route of Administration
11.5.3 India
11.5.3.1 Market Size and Forecast, By Type
11.5.3.2 Market Size and Forecast, By Application
11.5.3.3 Market Size and Forecast, By Route of Administration
11.5.4 South Korea
11.5.4.1 Market Size and Forecast, By Type
11.5.4.2 Market Size and Forecast, By Application
11.5.4.3 Market Size and Forecast, By Route of Administration
11.5.5 Australia
11.5.5.1 Market Size and Forecast, By Type
11.5.5.2 Market Size and Forecast, By Application
11.5.5.3 Market Size and Forecast, By Route of Administration
11.5.6 New Zealand
11.5.6.1 Market Size and Forecast, By Type
11.5.6.2 Market Size and Forecast, By Application
11.5.6.3 Market Size and Forecast, By Route of Administration
11.5.7 Singapore
11.5.7.1 Market Size and Forecast, By Type
11.5.7.2 Market Size and Forecast, By Application
11.5.7.3 Market Size and Forecast, By Route of Administration
11.5.8 Malaysia
11.5.8.1 Market Size and Forecast, By Type
11.5.8.2 Market Size and Forecast, By Application
11.5.8.3 Market Size and Forecast, By Route of Administration
11.5.9 Rest of Asia
11.5.9.1 Market Size and Forecast, By Type
11.5.9.2 Market Size and Forecast, By Application
11.5.9.3 Market Size and Forecast, By Route of Administration
12 Latin America Peptide Therapeutics Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Latin America Peptide Therapeutics Market Size and Forecast, By Type
12.3 Latin America Peptide Therapeutics Market Size and Forecast, By Application
12.4 Latin America Peptide Therapeutics Market Size and Forecast, By Route of Administration
12.5 Latin America Peptide Therapeutics Market Size and Forecast, By Country
12.5.1 Brazil
12.5.1.1 Market Size and Forecast, By Type
12.5.1.2 Market Size and Forecast, By Application
12.5.1.3 Market Size and Forecast, By Route of Administration
12.5.2 Argentina
12.5.2.1 Market Size and Forecast, By Type
12.5.2.2 Market Size and Forecast, By Application
12.5.2.3 Market Size and Forecast, By Route of Administration
12.5.3 Colombia
12.5.3.1 Market Size and Forecast, By Type
12.5.3.2 Market Size and Forecast, By Application
12.5.3.3 Market Size and Forecast, By Route of Administration
12.5.4 Peru
12.5.4.1 Market Size and Forecast, By Type
12.5.4.2 Market Size and Forecast, By Application
12.5.4.3 Market Size and Forecast, By Route of Administration
12.5.5 Chile
12.5.5.1 Market Size and Forecast, By Type
12.5.5.2 Market Size and Forecast, By Application
12.5.5.3 Market Size and Forecast, By Route of Administration
12.5.6 Venezuela
12.5.6.1 Market Size and Forecast, By Type
12.5.6.2 Market Size and Forecast, By Application
12.5.6.3 Market Size and Forecast, By Route of Administration
12.5.7 Rest of Latin America
12.5.7.1 Market Size and Forecast, By Type
12.5.7.2 Market Size and Forecast, By Application
12.5.7.3 Market Size and Forecast, By Route of Administration
13 Middle East Peptide Therapeutics Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Middle East Peptide Therapeutics Market Size and Forecast, By Type
13.3 Middle East Peptide Therapeutics Market Size and Forecast, By Application
13.4 Middle East Peptide Therapeutics Market Size and Forecast, By Route of Administration
13.5 Middle East Peptide Therapeutics Market Size and Forecast, By Country
13.5.1 Saudi Arabia
13.5.1.1 Market Size and Forecast, By Type
13.5.1.2 Market Size and Forecast, By Application
13.5.1.3 Market Size and Forecast, By Route of Administration
13.5.2 UAE
13.5.2.1 Market Size and Forecast, By Type
13.5.2.2 Market Size and Forecast, By Application
13.5.2.3 Market Size and Forecast, By Route of Administration
13.5.3 Egypt
13.5.3.1 Market Size and Forecast, By Type
13.5.3.2 Market Size and Forecast, By Application
13.5.3.3 Market Size and Forecast, By Route of Administration
13.5.4 Kuwait
13.5.4.1 Market Size and Forecast, By Type
13.5.4.2 Market Size and Forecast, By Application
13.5.4.3 Market Size and Forecast, By Route of Administration
13.5.5 South Africa
13.5.5.1 Market Size and Forecast, By Type
13.5.5.2 Market Size and Forecast, By Application
13.5.5.3 Market Size and Forecast, By Route of Administration
13.5.6 Rest of Middle East & Africa
13.5.6.1 Market Size and Forecast, By Type
13.5.6.2 Market Size and Forecast, By Application
13.5.6.3 Market Size and Forecast, By Route of Administration
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 F. Hoffmann-La Roche Ltd. (Switzerland)
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 GlaxoSmithKline plc (UK)
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3 Novartis AG (Switzerland)
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Pfizer, Inc. (U.S.)
15.4.1 Overview
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Sanofi (France)
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Takeda Pharmaceutical Company Limited (Japan)
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Teva Pharmaceutical Industries Ltd, (Israel)
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Ipsen Pharma (France)
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 AstraZeneca (UK)
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Lonza (Switzerland)
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies